A Garvan-led clinical trial has found that using a common and inexpensive type 2 diabetes drug reduces insulin needs in type 1 diabetes, opening doors for improved management of the condition.
By Tashi McQueenAFRO Staff [email protected] Type 2 diabetes mellitus (T2DM) is a chronic, life-altering condition affecting more than 35 million Americans. The disease occurs when a person’s ...
While type 1 and type 2 diabetes typically occupy distinct places in healthcare, research is showing an increase of patients ...
Women with polycystic ovary syndrome (PCOS) are increasingly using GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk, ...
Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...
5don MSN
Microbial molecule that disarms inflammation discovered, offering new diabetes treatment strategy
An international research team has uncovered a surprising ally in the fight against insulin resistance and type 2 diabetes: a ...
Researchers revealed that the microbial metabolite TMA can directly block the immune protein IRAK4, reducing inflammation and ...
She no longer needed insulin. What happened when one patient treated GLP-1 not as a shortcut but as a catalyst ...
Gut-microbe–derived trimethylamine (TMA) blocks a key immune protein, reducing inflammation and improving blood-sugar control.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback